Over the years, antimicrobial drugs have been widely used to treat microbial infectious diseases, including cholera, malaria, pneumonia, typhoid, and syphilis. Antibiotics are a form of drug formulation that has shown positive outcomes in treating a broad range of diseases. However, the efficacy of antibodies is declining continually due to the development of antimicrobial resistance.
According to the World Health Organization report, by 2030, nearly 5.2 million people will die from AMR (antimicrobial infection) in the Western Pacific Region. Moreover, the development of superbugs (antimicrobial strains of bacteria) has raised the concern of antibiotic resistance. The growing antimicrobial resistance creates difficulty in the treatment of disease in the future. Hence, the development of antibiotic resistance has surged the requirement for advanced drug formulation that can facilitate the treatment of diseases.
Antibiotics Market: Current Landscape Outlook
In the past few years, the antibiotics market has witnessed an upward trajectory owing to the rising demand for advanced therapeutic drugs to treat patients with antimicrobial drug resistance. According to the Roots Analysis report, the antibiotics market will grow and is expected to reach USD 41 billion by 2035, expanding at a CAGR of 1.2% from 2023-2035.
Furthermore, it is interesting to note here that more than 150 antibiotics are presently being evaluated under different stages of preclinical and clinical development. The focus on antibiotics market players will be on developing monotherapies and combinational therapies that can help to address the concern of growing antibiotic resistance. With an increasing pipeline of therapeutic drugs to treat infectious diseases is anticipated to drive the market in the future.
Top 5 Trends Driving Growth in the Market
It is worth highlighting here that in November 2021, the World Health Organization announced antimicrobial resistance as one of the leading threats across the globe. In order to meet the growing requirement for novel drugs, several active industrial leads in this domain follow an innovative approach to fight against developing antibiotic resistance.
- Precision Medicine: A Target-Specific Approach
With the development of antimicrobial resistance, the antibiotics market players have taken a shift towards personalized medicines. The tailored therapies serve as a potential alternative to meet with the growing concern of antimicrobial resistance. These precision treatment approaches involve the use of individual patient information, including molecular profiling, genome profiling, and metabolomics.
The tailored approach helps pharmaceutical researchers gain better insight into diseases and specific treatments to cure patients of specific disorders. Precision medicine has shown promising results in treating diseases, including cancer. Considering the benefits, researchers will explore more applications to treat a broad range of diseases, which is anticipated to drive the market in the future.
- Advance Immunotherapies Market
In order to mitigate the risk of antibiotic resistance, researchers are developing advanced therapies such as immunotherapy, microbiome-based therapies, phage therapies, and combinational therapies. These therapies involve monoclonal antibodies and drug components that can treat patients with a target-specific approach. Immunotherapies harness the potential of immune cells to target disease or non-functional cells.
The tailored approach helps to treat patients who are suffering from multi-drug resistance and are unable to get relief from conventional drugs. With the growing shift towards advanced therapies, antibiotics market leaders are leveraging technologies to develop innovative therapies, which are estimated to propel growth in the field.
- Nanoantibiotics
In the past few years, nanoantibiotics have gained significant attention as a potential alternative to treat patients with antimicrobial resistance. This involves the use of metal oxide-based nanoparticles combined with antibiotics. Nanoantibiotics pose high antibacterial efficacy and cause less toxicity to the patients; driven by their efficiency, they serve as a potential therapeutic application to treat diseases in the future.
- Emphasize on Microbiome Based Therapies
With an increasing understanding of the microbiome and their role in disease management, several pharmaceutical players are emphasizing the development of microbiome-based therapies. These therapies can easily be modified based on the individual’s molecular characteristics and microbiome profiling. This microbiome-based approach facilitates the treatment of patients with a broad spectrum of disease indications. Further, the growing shift towards microbiome-based therapies and ongoing research to combat the risk of antimicrobial resistance is driving growth in this domain.
- Next-Generation Sequencing Methods
In recent years, the antibiotics market has witnessed an increasing risk of antimicrobial resistance owing to the excessive use of drugs. It is worth highlighting here that advances in technologies such as next-generation sequencing enable researchers to understand the mechanism behind developing resistance within bacteria. The technology enables clinicians to use vital information about bacterial resistance to develop target-specific antibiotics and tailored therapies to treat patients. Furthermore, the technology also enables researchers to design personalized treatments and novel antibiotics, which is projected to drive the market in the future.
Collaborations and Partnerships in Antibiotics Market
The antibiotics market is witnessing several partnerships and collaborations between industrial and non-industrial leaders engaged in this field. Notably, 30% of these partnerships have been signed between the leaders in 2022. The aim of the partnerships is to increase efforts towards the development of advanced therapeutic drugs and tailored specific therapies to treat patients.
Some of the recent partnerships that have taken place in this field are listed below:
- In August 2023, Bugworks Research entered into collaboration with Global Antibiotic Research and Development to accelerate the development of antibiotic compounds to treat infection occurred due to multi-drug resistant bacteria.
- In May 2023, Melinta Therapeutics and Xediton Pharmaceuticals entered into a commercialization and licensing agreement in order to launch BAXDELA®, KIMYRSA®, ORBACTIV® and VABOMERE® in Canada.
In a nutshell, antibiotic resistance is a major concern across the globe—the development of multi-drug resistance creates enormous challenges for healthcare professionals to treat diseases. As a result, antibiotics market players are emphasizing the development of tailored therapies to treat various disease indications. In the near future, pharmaceutical companies are leveraging advanced technologies, including artificial intelligence and multi-omics, to develop novel drugs that facilitate the treatment of patients. Driven by the ongoing efforts for the development of therapies, the antibiotics market will witness stable growth in the future.
Reference: https://www.rootsanalysis.com/reports/global-antibiotics-market.html
